Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Camptothecin + Gedatolisib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Camptothecin | 21,22-Secocamptothecin-21-oic acid lactone|Camptothecine | TOPO1 inhibitor 11 | Camptothecin is a natural product alkaloid topoisomerase I inhibitor from which irinotecan and topotecan are derived (PMID: 16990856, PMID: 32585151) | |
Gedatolisib | PKI-587|PF-05212384|PF 05212384 | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | Gedatolisib (PF-05212384) is an ATP-competitive inhibitor that targets phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, and may result in antitumor activity, including inhibition of tumor growth and tumor regression (PMID: 21325073, PMID: 31822716). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|